OKYO Pharma's Urcosimod Shows Clinically Meaningful Pain Reduction in Phase 2a NCP Trial; Advances to Phase 2b/3

summarizeSummary

This filing provides a significant positive update on OKYO Pharma's lead drug candidate, urcosimod, for neuropathic corneal pain (NCP). The successful Phase 2a proof-of-concept results, demonstrating clinically meaningful pain reduction and quality-of-life improvements, are a major de-risking event for a clinical-stage biopharmaceutical company. The drug's potential to restore corneal nerve structure further enhances its profile. Given NCP's status as an unmet medical need with no FDA-approved treatments and urcosimod's Fast Track designation, these results position the company for a critical next phase of development. The planned initiation of a larger Phase 2b/3 trial in the near future indicates strong confidence in the data and the drug's potential. This positive clinical news provides a strong fundamental catalyst, especially following recent dilutive financing activities.

check_boxKey Events

• Positive Phase 2a Results for Urcosimod

  Urcosimod demonstrated clinically meaningful pain reduction and improved quality-of-life in a first-in-human study for Neuropathic Corneal Pain (NCP).

• Potential for Corneal Nerve Restoration

  The study also showed urcosimod's potential to help restore corneal nerve structure in NCP patients.

• Advancing to Phase 2b/3 Trial

  Following these proof-of-concept results, OKYO Pharma plans to initiate a larger multicenter Phase 2b/3 trial (approximately 150 patients) in the first half of this year.

• Accepted for ARVO Presentation

  The positive data has been accepted for presentation at the prestigious Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting.

auto_awesomeAnalysis

This filing provides a significant positive update on OKYO Pharma's lead drug candidate, urcosimod, for neuropathic corneal pain (NCP). The successful Phase 2a proof-of-concept results, demonstrating clinically meaningful pain reduction and quality-of-life improvements, are a major de-risking event for a clinical-stage biopharmaceutical company. The drug's potential to restore corneal nerve structure further enhances its profile. Given NCP's status as an unmet medical need with no FDA-approved treatments and urcosimod's Fast Track designation, these results position the company for a critical next phase of development. The planned initiation of a larger Phase 2b/3 trial in the near future indicates strong confidence in the data and the drug's potential. This positive clinical news provides a strong fundamental catalyst, especially following recent dilutive financing activities.